DelveInsight’s “Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Knee Osteoarthritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Knee Osteoarthritis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Knee Osteoarthritis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Knee Osteoarthritis: An Overview
Knee osteoarthritis (OA), also known as degenerative joint disease, is typically the result of wear and tear and progressive loss of articular cartilage. It is most common in the elderly and can be divided into two types, primary and secondary. Primary osteoarthritis is articular degeneration without any apparent underlying reason. Secondary osteoarthritis is the consequence of either an abnormal concentration of force across the joint as with post-traumatic causes or abnormal articular cartilage, such as rheumatoid arthritis (RA).
The symptoms of Knee Osteoarthritis usually develop gradually. This is because it takes time for the cartilage to wear down and change the way your joints work. However, sudden onset of symptoms is possible—but not as common. Knee symptoms can vary depending on the cause of the problem. The most common symptom of knee Osteoarthritis is pain around the knee joint. Pain can be dull, sharp, constant, or intermittent (off and on). Pain can vary from mild to agonizing.
Knee Osteoarthritis is closely associated with age, as radiographic evidence of Knee Osteoarthritis occurs in most people by age 65 years and in more than 75% of people older than age 75 years. Although there are many associations and mechanisms that are not well understood, it has been reported that there is a higher prevalence of Knee Osteoarthritis among older women.
Expected launch of potential therapies by key players like Techfields (X0002), Taiwan Liposome Company (TLC599), Centrexion Therapeutics (CNTX-4975), Biosplice Therapeutics (Lorecivivint), Ampio Pharmaceuticals (Ampion), Paradigm Biopharmaceuticals (Zilosul), Grünenthal (RTX-GRT7039/Resiniferatoxin), Naturecell (JointStem), and others is expected to improve the treatment outlook in the upcoming years.
Knee Osteoarthritis Market Key Facts
According to the estimates, the highest market size of Knee Osteoarthritis was found in the United States and the least was in Italy, across the 7MM.
The prevalent population of symptomatic Knee Osteoarthritis in the seven major markets was found to be 47,874,000+ in 2021.
In 2021, the highest prevalent cases of the disease were observed in the United States, with 17,660,000+ cases, and EU4 and the UK accounted for 19,946,000+ cases.
In EU4 and the UK, in 2021, the highest proportion of age-specific cases was observed in 70 years and above, followed by age groups of 60–69 years and 50–59 years. In 2021, there were 638,000+, 1,735,000+, 4,328,000+, 4,807,000+, and 8,437,000+ cases, in the age groups 18–39 years, 40–49 years, 50–59 years, and 60–69 years and 70 years and above, respectively.
Japan accounted for 10,267,000+ prevalent symptomatic Knee Osteoarthritis cases in 2021.
Knee Osteoarthritis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Knee Osteoarthritis pipeline therapies. It also thoroughly assesses the Knee Osteoarthritis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Knee Osteoarthritis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Knee Osteoarthritis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Knee Osteoarthritis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Knee Osteoarthritis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Knee Osteoarthritis Epidemiology, Segmented as –
Prevalent Population of Knee Osteoarthritis in the 7MM [2019–2032]
Gender-specific Prevalence of Knee Osteoarthritis in the 7MM [2019–2032]
Age-specific Prevalence of Knee Osteoarthritis in the 7MM [2019–2032]
Severity-specific Prevalence of Knee Osteoarthritis the 7MM [2019–2032]
Knee Osteoarthritis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Knee Osteoarthritis market or expected to be launched during the study period. The analysis covers the Knee Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Knee Osteoarthritis drugs based on their sale and market share.
The report also covers the Knee Osteoarthritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Knee Osteoarthritis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Knee Osteoarthritis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/knee-osteoarthritis-market
Knee Osteoarthritis Therapeutics Analysis
Currently, there are several pharmacologic treatments available for the management of knee OA–related pain and for improving its functionality. These common pharmacologic interventions used to help alleviate the symptoms of Knee Osteoarthritis include non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids, intra-articular hyaluronic acid, and well as opioids.
Non-pharmacological therapies should always be attempted as the first line of treatment for Knee Osteoarthritis like, exercise, weight management, and adjunct therapies. Historically, cyclooxygenase inhibitors (acetaminophen and NSAIDs) have been the most commonly used medications after non-pharmacological therapies. Further opioids, corticoids, and visco supplements are used for the Knee Osteoarthritis treatment.
Several major pharma and biotech companies developing therapies for Knee osteoarthritis. Currently, Bone Therapeutics is leading the therapeutics market with its Knee osteoarthritis drug candidates in the most advanced stage of clinical development.
“On 13 June 2023, Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for the investigation of EP-104IAR in the treatment of adults with osteoarthritis (“OA”) of the knee.”
Knee Osteoarthritis Companies Actively Working in the Therapeutics Market Include
Abbvie, Akan Biosciences, Ampio Pharmaceuticals, Amzell, Anika Therapeutics, AstraZeneca, BioIntegrate, Bioventus LLC, Bone Therapeutics, CAR-T (Shanghai) Biotechnology, Celltex Therapeutics Corporation, Centrexion Therapeutics, Eli Lilly and Company, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gwo Xi Stem Cell Applied Technology, Meluha Life Sciences SDN BHD, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Moebius Medical, Novartis, Orient Europharma Co., Ltd., OrthoTrophix, Paradigm Biopharmaceuticals, Peptinov SAS, Personalized Stem Cells, Propella Therapeutics, PT. Prodia Stem Cell Indonesia, Purdue Pharma, R-Bio, Regeneron Pharmaceuticals, Samumed LLC, Sclnow Biotechnology, Sorrento Therapeutics, Swiss Medica XXI Century S.A., Taiwan Liposome Company, Techfields Pharma, UnicoCell Biomed CO. LTD, Vivex Biomedical, Xalud Therapeutics, Yooyoung Pharmaceutical, and many others.
Emerging and Marketed Knee Osteoarthritis Therapies Covered in the Report Include:
JTA-004: Bone Therapeutics
MM-II: Moebius Medical
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Knee Osteoarthritis Competitive Intelligence Analysis
4. Knee Osteoarthritis Market Overview at a Glance
5. Knee Osteoarthritis Disease Background and Overview
6. Knee Osteoarthritis Patient Journey
7. Knee Osteoarthritis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Knee Osteoarthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Knee Osteoarthritis Unmet Needs
10. Key Endpoints of Knee Osteoarthritis Treatment
11. Knee Osteoarthritis Marketed Therapies
12. Knee Osteoarthritis Emerging Drugs and Latest Therapeutic Advances
13. Knee Osteoarthritis Seven Major Market Analysis
14. Attribute Analysis
15. Knee Osteoarthritis Market Outlook (In US, EU5, and Japan)
16. Knee Osteoarthritis Companies Active in the Market
17. Knee Osteoarthritis Access and Reimbursement Overview
18. KOL Views on the Knee Osteoarthritis Market
19. Knee Osteoarthritis Market Drivers
20. Knee Osteoarthritis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Physiotherapy Equipment Market
The global Physiotherapy Equipment Market was valued at USD 18.67 billion in 2021, growing at a CAGR of 7.44% during the forecast period from 2023 to 2028; it is expected to reach USD 28.62 billion by 2028. Some of the key companies such as BTL, Ito Co Ltd, EMS Physio Ltd, Dynatronics Corporation, COMPASS HEALTH BRANDS CORP, Performance Health, Zynex Medical Inc, DJO LLC, Whitehall Manufacturing, Zimmer Medizin Systeme GmbH, STORZ MEDICAL AG, Mettler Electronics Corp, A. Algeo Ltd, HMS Medical Systems, Johari Digital, NEVRO CORP, BioElectronics Corporation, among others are actively working in the Physiotherapy Equipment Market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/medical-devices
